AsedaSciences, Clyde Biosciences sign agreement to integrate cardiotoxicity screen
AsedaSciences signed a commercial agreement with Clyde Biosciences to integrate the CellOPTIQ cardiotoxicity screen into its 3RnD platform. The deal adds a validated in vitro CiPA assay for chemical and drug safety assessment.
AsedaSciences announced a Strategic Sales and Marketing Agreement with Clyde Biosciences to integrate Clyde Bio’s CellOPTIQ cardiotoxicity platform into the AsedaSciences 3RnD platform and testing ecosystem. The agreement adds a human-relevant cardiotoxicity screen for chemical safety assessment to the 3RnD platform. The CellOPTIQ platform generates high-content, human-relevant cardiomyocyte functional data for chemical and drug safety assessment.
Within the 3RnD ecosystem, Clyde Bio’s cardiotoxicity screen can be deployed as either a front-line or confirmatory assay for overall cardiotoxicity risk assessment. Its integration complements other organ-level, mechanistic, receptor, and pathway-based screens already being incorporated into the platform. The companies said these technologies enable tiered testing strategies that combine mechanistic insight with functional organ-level outcomes while centralizing resulting data for integrated analysis and visualization.
The CellOPTIQ platform is described as the only validated in vitro Proarrhythmia Assay (CiPA) capable of simultaneously measuring voltage, calcium and contractility in the same cardiomyocytes. The platform has been extensively validated through projects with the majority of large pharmaceutical companies and through collaborations with CiPA, HESI, and the U.S. Food and Drug Administration.
As part of the agreement, the companies said they will jointly expand a comparative reference library within the 3RnD platform. The library will allow users of the Clyde cardiotoxicity screen and other integrated assays to benchmark results against historical and reference compound data. By integrating chemical structure, functional cardiomyocyte data, and mechanistic assay outputs, 3RnD is intended to support earlier decisions around compound selection, prioritization, progression, and structure-activity relationship optimization.
The companies said the collaboration reflects movement away from animal testing toward human-relevant New Approach Methods. Clyde Bio’s platform provides predictive cardiomyocyte-based assays, and the 3RnD platform is designed as an integrated digital ecosystem for selecting, prioritizing, and progressing safer chemicals.